Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Daniel Ambinder

Interventional & Structural Cards · UMSOM

View

Dr. Amit Goyal

Interventional & Structural Cards · UT Southwestern

View

Dr. David Cohen

Interventional & Structural Cards · Cardiovascular Research Foundation

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View

Dr. Felix Yang

EP · NYU Langone

View

Dr. Jennifer Rymer

Interventional & Peripheral Cards · Duke University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Impact of Atrial Fibrillation in Patients With Severe Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.

    Jul 17, 2025DOI: 10.1161/jaha.125.042016Journal ArticleAHA

    Written by: Carlo ManninaAkarsh SharmaYash PrakashAndreina CarboneEduardo BossoneAntonino TuttolomondoEdgar ArgulianSahil KheraParasuram Melarcode-KrishnamoorthyGeorge DangasJonathan HalperinGilbert H L TangSamin SharmaAnnapoorna KiniGregg W StoneStamatios Lerakis

    Find these authors on Roon

    PM
    Dr. Parasuram Melarcode krishnamoorthy
    Interventional & Structural Cards · OUHSC

    METHODS

    The data that support the findings of this study are available from the corresponding author upon reasonable request.Consecutive patients aged 18 years or older referred for M‐TEER at a single academic medical center (Mount Sinai Fuster Heart Hospital, New York, NY) between January 2021 and December 2023 with severe (grade 3+ or 4+) MR were included.All participants underwent comprehensive 2‐dimensional and Doppler transthoracic echocardiography at baseline and during follow‐up using commercially available ultrasound systems. For patients with multiple echocardiograms during follow‐up, the values from the last available study before the end of follow‐up were used. Conventional echocardiographic parameters were measured in accordance with the guidelines established by the American Society of Echocardiography.11, 12 The severity of MR and decision to perform M‐TEER were determined by consensus of a multidisciplinary heart team. Echocardiograms were interpreted by a structural echocardiographer (S.L.) with measurements performed without knowledge of the patients' clinical features.The history, baseline clinical characteristics, and echocardiographic and procedural details were recorded by treating physicians and extracted from electronic medical records. AF was defined by its presence on the ECG performed on the day of the M‐TEER procedure before intervention. The observation period began on the date of intervention and continued until the last follow‐up visit or death.The study was approved by the institutional review board at the Icahn School of Medicine at Mount Sinai. Informed consent was waived due to the retrospective nature of the investigation.The primary end point of interest was the composite of all‐cause mortality or HFH after M‐TEER. Secondary end points were the individual components of the composite end point and changes in echocardiographic parameters, including left ventricular (LV) end‐diastolic volume index, LV end‐systolic volume index, LV ejection fraction, LV mass index, left atrial volume index (LAVI), right ventricular systolic pressure (RVSP), and MR recurrence at follow‐up.Follow‐up data were obtained through review of medical records. Deaths were confirmed through cross‐referencing with the Limited Access Death Master File. Data from patients lost to follow‐up were censored at the time of last known contact. Periprocedural complications were defined in accordance with the Valve Academic Research Consortium‐3 definitions.13Continuous variables were expressed as the median and interquartile range and categorical variables as values and percentages. Baseline and echocardiographic characteristics were assessed using the Kruskal–Wallis test, Mann–Whitney U test, and Pearson's chi‐square statistics. The Wilcoxon signed‐rank test for paired samples was used to analyze changes in echocardiographic parameters, and McNemar's test was used to analyze the change in New York Heart Association functional classification after M‐TEER, compared with baseline. Kaplan–Meier methodology was used to construct time‐to‐first event curves, and the differences between groups were assessed using the log‐rank test. Multivariable analysis was performed to investigate the independent association of AF with the primary composite outcome after M‐TEER. Covariates included in the multivariable models were selected based on prior studies that established variables associated with mortality and HF outcomes.14, 15 To evaluate changes in echocardiographic parameters by AF status while accounting for variability in follow‐up echocardiography timing, we performed linear regression analyses modeling the change in each echo variable as the outcome. Each model included AF status, the baseline value of the corresponding variable, and time to follow‐up echocardiography as covariates. We also tested for an interaction between AF status and follow‐up time. Estimates are reported as hazard ratio (HR) and 95% CIs. A 2‐tailed P value <0.05 was considered statistically significant for all analyses. All statistical analyses were performed with STATA v19, (Stata Corp, College, TX).

    RESULTS

    Between January 2021 and August 2023, 156 consecutive patients with severe MR underwent M‐TEER. AF was present in 59 patients (37.8%) and sinus rhythm (SR) was present in 97 (62.2%) patients (including 37 patients with a prior history of AF who were in SR at the time of the M‐TEER procedure). Baseline clinical characteristics and medication use stratified by the presence of AF are shown in Table 1. Mean age was 80.8±8.8 years, 82 (56.6%) were female, and all patients were symptomatic, with 140 (89.7%) in New York Heart Association class III. Most baseline characteristics were similar in patients with and without AF, except that those with AF were more likely to have secondary MR (43 [72.9%] versus 48 [49.5%], P=0.004), higher body mass index, and history of stroke. At the time of the procedure, patients with AF were clinically stable and were more frequently treated with beta blockers (86.4% versus 68.0%, P=0.03) and loop diuretics (79.7% versus 63.9%, P=0.04) compared with those in SR. Patients with AF had similar LV volumes and LV ejection fractions, but a larger LAVI and more frequent tricuspid regurgitation of at least moderate severity, despite similar RVSP compared with patients in SR (Table 2). Conversely, the quantitative severity of MR as measured by the effective regurgitant orifice area and regurgitant volume were greater in patients in SR (P=0.06 and P=0.04, respectively).Baseline Clinical Variables and Medication Use Stratified by the Presenting RhythmValues are presented as median (25th–75th percentile) or n (%). AF indicates atrial fibrillation/flutter; and SR, sinus rhythm.Baseline Echocardiographic Parameters Stratified by the Presenting RhythmValues are presented as median (25th–75th percentile) or n (%). AF indicates atrial fibrillation; LV, left ventricular; MR, mitral regurgitation; and SR, sinus rhythm.Table 3 summarizes the transesophageal echocardiographic findings after M‐TEER. M‐TEER was equally successful in patients with AF and SR in achieving moderate or less (0 to 2+) MR (58 [98.3%] versus 94 [96.9%], respectively, P=0.59) and mild or less (0 or 1+) MR (55 [93.2%] versus 84 [86.6%], respectively, P=0.20).M‐TEER Procedural Outcomes Stratified by the Presenting RhythmValues are presented as median (25th–75th percentile) or n (%). AF indicates atrial fibrillation; M‐TEER, mitral transcatheter edge‐to‐edge repair; and SR, sinus rhythm.Median follow‐up was 12.5 (5.4–17.4) months (13.2 [4.2–21.8] for AF versus 11.5 [6.0–17.4] months for SR, P=0.38). One‐year follow‐up was performed in 60/97 (61.9%) patients in SR and in 29/59 (49.2%) patients with AF; the remaining patients had shorter follow‐up durations. The primary end point occurred in 64 patients (2‐year Kaplan–Meier estimated rate 41.0%), including death in 16 patients (10.3%) and HFH in 57 patients (36.5%). At 2 years, death or HFH had occurred in 31 (52.5%) of patients with AF versus 32 (33.0%) with SR (unadjusted HR, 1.88 [95% CI, 1.14–3.08], P=0.01) (Figure 1A). Mortality occurred more frequently in patients with AF compared with SR (9 [15.3%] versus 7 [7.1%]; unadjusted HR, 2.30 [95% CI, 0.86–6.18], P=0.10), as did HFH (28 [47.5%] versus 29 [29.9%]; unadjusted HR, 1.71 [95% CI, 1.02–2.88], P=0.04) (Figure 1B and 1C). The differences between the groups in the rates of stroke were not significant (Figures 1D). By multivariable analysis, AF remained a significant independent predictor of death or HFH during follow‐up (HR, 2.03 [95% CI, 1.12–3.69], P=0.02) (Table 4).A, Death or HFH. B, Death. C, HFH. D, Stroke. HFH indicates heart failure hospitalization; HR, hazard ratio; and M‐TEER: mitral transcatheter edge‐to‐edge repair.Baseline Predictors of the Primary Composite Outcome of Death or HFH After M‐TEERHFH indicates heart failure hospitalization; HR, hazard ratio; LV, left ventricular; and M‐TEER: mitral transcatheter edge‐to‐edge repair.Follow‐up echocardiography was completed in 147/156 patients (94.2%) at a median time of 6.0 (1.0–12.2) months (12.0 [1–14.3] for AF versus 7 [1–12 months] for SR, P=0.18). As shown in Figure 2, LV end‐diastolic volume index, LAVI, and RVSP decreased during follow‐up only in patients with SR, whereas RVSP increased in those with AF. LV end‐systolic volume index and LV mass index decreased in both groups, whereas LV ejection fraction remained unchanged. Patients with AF compared with SR were more likely to have severe (3+ or 4+) MR at follow‐up (18.6% versus 8.2%, P=0.05) (Figure 3). No significant interactions between AF status and follow‐up duration were observed for changes in echocardiographic parameters.A, LVEDVI. B, LVESVI. C, LVEF. D, LVMI. E, LAVI. F, RVSP. LAVI indicates left atrial volume index; LVEDI, left ventricular end‐diastolic volume index; LVEF, lLeft ventricular ejection fraction; LVESI, left ventricular end‐systolic volume index; LVMI, left ventricular mass index; M‐TEER: mitral transcatheter edge‐to‐edge repair; and RVSP, right ventricular systolic pressure.MR indicates mitral regurgitation.Of note, although no deaths occurred during the index hospitalization, 12 events (4 deaths and 8 HFHs) occurred within 30 days of the procedure (5 events in patients in SR and 7 events in patients in AF). To examine the effect of cardiac rhythm on late outcomes, we performed a landmark analysis beginning at 30 days. AF remained associated with adverse outcomes between 30 days and 2 years (adjusted HR [aHR], 2.95 [95% CI, 1.27–6.87], P=0.01) (Figure S1, Table S1).A sensitivity analysis was also performed including all patients with a documented history of AF in the group with AF, regardless of rhythm at the time of the procedure. In this analysis 96 patients with a history of AF (including 59 with AF at the time of the procedure and 37 patients with a history of AF who were in SR at the time of the procedure) were compared with 60 patients in SR who had no history of prior AF. Tables S2 and S3 show the baseline clinical and echocardiographic parameters based on history of AF. In this analysis, a history of AF was associated with an increased risk of death or HFH in univariable analysis (HR, 1.82 [95% CI, 1.05–3.14], P=0.03) (Figure S2). However, this association was no longer significant after adjustment for clinical covariates (aHR, 1.78 [95% CI, 0.93–3.42], P=0.08) (Table S4).

    DISCUSSION

    In this study, patients with AF at the time of M‐TEER had worse cardiovascular outcomes than those in SR at baseline, with increased risk of both death and HFH during 2‐year follow‐up. There were no differences in the incidence of stroke. Patients with SR also had favorable LV, LA, and RV remodeling during follow‐up, as indicated by improved LV end‐diastolic volume index, LAVI, and RVSP, whereas patients in AF did not. Finally, patients with AF had more severe MR and worse RVSP after during follow‐up. By multivariable analysis, AF remained a significant independent predictor of death or HFH during follow‐up after M‐TEER.Current clinical practice guidelines recommend mitral valve repair when possible for asymptomatic patients with severe primary (degenerative) MR who develop AF with preserved LV size and function and AF.16 M‐TEER is reserved for patients at high or prohibitive risk for surgery but is increasingly used in lower risk patients as well.17 The results of the COAPT, MITRA‐FR (MitraClip Device for Severe Functional/Secondary Mitral Regurgitation), and RESHAPE‐HF2 (Transcatheter Valve Repair in Heart Failure With Moderate to Severe Mitral Regurgitation) trials support M‐TEER as the primary approach for patients with severe secondary (functional) MR. However, whereas the adverse impact of preoperative AF on patients undergoing surgical MV repair has been established,18 the impact of this arrhythmia after M‐TEER is less clear. A multicenter study across 5 centers in the Netherlands analyzing 618 patients who underwent M‐TEER reported that mortality and MR recurrence were similar among those with and without baseline AF at 1‐year follow‐up.9 Similarly, in EVEREST II (Endovascular Valve Edge‐to‐Edge Repair Study), there was no difference in all‐cause mortality between patients with and without AF.19 Conversely, data from the TVT (Transcatheter Valve Therapy) and TRAMI (Transcatheter Mitral Valve Interventions) registry showed worse survival at 12 months for patients with AF after M‐TEER.15, 20In contrast to most prior reports, in our study, AF was defined based on the rhythm documented on the ECG performed on the day of and before the M‐TEER procedure, maximizing the risk that AF might be deleterious (as opposed to a remote history of AF that might not recur). Nonetheless, a successful M‐TEER procedure was achieved equally in patients with SR and AF. However, our study confirmed an independent risk of AF on the composite outcome of all‐cause death or HFH due to increased risk of both mortality and HFH during 2‐year follow‐up compared with the outcomes observed in patients in SR at the time of M‐TEER. The negative effect of baseline AF was especially evident beyond 30 days after the M‐TEER procedure and was reflected in greater risk of death and HFH as well as worse LV remodeling, increase in RVSP and greater recurrent severe MR. Compared with the EVEREST II trial, our cohort represented a higher‐risk population, with older age (mean 80.8 versus 68.5 years), lower LV ejection fraction (50.6% versus 60%), and a greater proportion of patients in New York Heart Association functional class III/IV (89.1% versus 49.2%).19 These differences likely contributed to the higher observed mortality in our study, consistent with the expectations of real‐world clinical data as opposed to a controlled trial population. Also of note, patients with AF at baseline likely had a higher burden of AF than the broader group of patients with a history of AF that included patients with prior paroxysmal AF who were in SR at the time of the M‐TEER procedure. This likely explains why AF at baseline was an independent predictor of death or HFH after M‐TEER, whereas any history of AF was not.The mechanisms responsible for the worse cardiovascular outcomes in patients with AF undergoing M‐TEER are uncertain but may be related to structural and functional echocardiographic differences after the intervention. Prior evidence suggested that the adverse consequences in patients with a history of AF may be related to differences in demographic and clinical characteristics at baseline, such as older age,9, 15 chronic kidney disease,21 or more advanced valvular disease.22 In our study we did not see differences in patient age or valvular disease severity in those with AF and SR. Rather, patients with SR exhibited more favorable LV, LA, and RV remodeling after M‐TEER indicated by lower LV end‐diastolic volume index, LAVI, RVSP, and MR ≥2 recurrence within 6 to 12 months after the M‐TEER procedure. Mean RSVP also decreased during follow‐up after M‐TEER in patients with SR but increased in those with AF, likely contributing to their worse prognosis. Our results confirm prior findings that suggested more favorable LA and LV remodeling in patients in SR19; however, we also found a higher risk of severe MR recurrence at follow‐up compared with prior studies,9 possibly due to a higher prevalence of a primary MR in our cohort.The development of AF in the patient with MR may reflect worse structural and functional MR severity and unfavorable LA, LV, and RV remodeling in response to the valve lesion.7 Our study suggests AF may also indicate a relatively worse prognosis after M‐TEER compared with that expected in patients with SR. Similarly, patients with recurrent AF after catheter ablation had greater LA dilation and MR than those in whom SR was sustained.23 Rhythm control has been proposed as a means of promoting atrial reverse remodeling and restoring atrioventricular coupling.24, 25, 26 Prior evidence has advocated surgical MV repair to avoid the detrimental effects of AF.27 To date, no data are available regarding whether M‐TEER reduces the future incidence or burden of AF. The present study warrants the need for adjuvant strategies to optimize outcomes in patients with established AF undergoing transcatheter MV repair. In this regard surgical ablation for AF has become common during MV surgery and has been shown to improve prognosis.28The TVT registry reported an increased risk of stroke within the first year after M‐TEER in patients with AF compared with SR.29 In contrast, we found no difference in the incidence of stroke between patients with SR and AF, possibly due to a higher prevalence of anticoagulant therapy in our cohort than in the TVT registry (81.4% versus 62.6%).To our knowledge the present study is the first to comprehensively evaluate the impact of AF at the time of the procedure on the risk of HF, mortality, and subsequent cardiac function and structural remodeling following M‐TEER in patients with severe primary and secondary MR. Careful use of multivariable modeling was used to adjust for covariates that might be common with AF and otherwise impair prognosis. However, several limitations should be noted. First, the study population predominantly included older adults, which is representative of patients who most commonly undergo M‐TEER; therefore, our results may not apply to younger individuals. Second, the retrospective and observational design of the study may not have identified all confounders and limits the ability to establish a cause–effect relationship. Third, the single center nature of our study and modest sample size and number of events limits its generalizability and robustness, with replication needed from additional centers and in more patients. Similarly, we were not adequately powered to determine whether an incremental risk was present in patients with SR at the time of M‐TEER who had a prior history of AF. Fourth, the SR group included patients with a history of AF; in this group the duration of SR and the burden of prior AF were unknown, and of course some patients in SR without a prior history of AF may indeed have had AF at some point. The impact of these uncertainties is unknown. Fifth, although the effect size of AF was similar in the primary analysis and a sensitivity analysis in which patients in SR with a history of AF were included in the group with AF, in the latter analysis the risk of AF did not reach significance, possible representing a type II error. Further studies are required to determine if patients with SR and a history of AF are at intermediate risk between those with AF at the time of the procedure and those without any history of AF. Sixth, although we adjusted for baseline values, we cannot exclude that regression to the mean did not affect the change in echo parameters over time. Finally, AF was not captured during follow‐up, and thus the present analysis does not account for the impact of recurrent AF in patients with SR (or conversion to SR in patients with AF).

    CONCLUSIONS

    In patients with HF and severe MR undergoing M‐TEER, despite comparable acute results as in patients with SR, baseline AF at the time of the procedure was associated with more than doubling of the risk of death or HFH during 2‐year follow‐up. These results were less pronounced in patients with a history of AF.Patients with AF at the time of the M‐TEER procedure exhibited impaired LV, LA, and RV remodeling during 1‐year follow‐up and had higher RVSP compared with patients in SR. Patients with AF also had more frequent recurrence of severe MR during follow‐up.Whether adjunctive rhythm control strategies to prevent or correct AF before or after M‐TEER would improve both cardiac function and clinical outcomes requires further investigation.

    Sources of Funding

    None.

    Disclosures

    Dr Stone has received speaker honoraria from Medtronic, Amgen, Boehringer Ingelheim; has served as a consultant to Robocath, Daiichi Sankyo, Vectorious, Miracor, Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, Remote Cardiac Enablement, Ablative Solutions, Abbott, Valfix, Zoll, HeartFlow, Shockwave, Impulse Dynamics, Adona Medical, Oxitope, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical, Myochron, Colibri; and has equity/options from Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter. Dr. Stone's employer, Mount Sinai Hospital, receives research grants from Shockwave, Biosense‐Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc., Phillips, Vascular Dynamics, Pulnovo, V‐wave, and Patient‐Centered Outcomes Research Institute (via Weill Cornell Medical Center). The other authors have no disclosures. Dr Khera is proctor and consultant of Medtronic and Abbott; has served as a consultant of Edwards Lifesciences. Dr Tang has received speaker's honoraria and served as a physician proctor, consultant, advisory board member, TAVR publications committee member, RESTORE study steering committee member, APOLLO trial screening committee member and IMPACT MR steering committee member for Medtronic, has received speaker's honoraria and served as a physician proctor, consultant, advisory board member and TRILUMINATE trial anatomic eligibility and publications committee member for Abbott Structural Heart, has served as an advisory board member for Boston Scientific; a consultant and physician screening committee member for Shockwave Medical; a consultant for Philips and Edwards Lifesciences, Peija Medical, and Shenqi Medical Technology; and has received speaker's honoraria from Siemens Healthineers.

    Supporting information

    Tables S1–S4Figures S1–S2
    PMDr. Parasuram Melarcode krishnamoorthy

    Dr. Parasuram Melarcode krishnamoorthy

    Cardiology · Interventional Cardiology & Structural
    University of Oklahoma Health Sciences Center
    parasuram